{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T02:22:35Z","timestamp":1783131755612,"version":"3.54.6"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007880","name":"Johns Hopkins University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007880","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006501","name":"Cystic Fibrosis Foundation Therapeutics Inc","doi-asserted-by":"publisher","award":["RIEKER23PE0"],"award-info":[{"award-number":["RIEKER23PE0"]}],"id":[{"id":"10.13039\/100006501","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006501","name":"Cystic Fibrosis Foundation Therapeutics Inc","doi-asserted-by":"publisher","award":["SAWICK14PE1"],"award-info":[{"award-number":["SAWICK14PE1"]}],"id":[{"id":"10.13039\/100006501","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006501","name":"Cystic Fibrosis Foundation Therapeutics Inc","doi-asserted-by":"publisher","award":["YETI23PE0"],"award-info":[{"award-number":["YETI23PE0"]}],"id":[{"id":"10.13039\/100006501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.rmed.2026.108908","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T06:58:00Z","timestamp":1779865080000},"page":"108908","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["People with cystic fibrosis\u2019 experience of symptom burden while taking elexacaftor\/tezacaftor\/ivacaftor"],"prefix":"10.1016","volume":"259","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7981-205X","authenticated-orcid":false,"given":"Emily F.","family":"Muther","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidney L.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3855-770X","authenticated-orcid":false,"given":"Christine","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6892-3512","authenticated-orcid":false,"given":"Kristin A.","family":"Riekert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordana E.","family":"Hoppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Prickett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6084-5775","authenticated-orcid":false,"given":"Megan von","family":"Isenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6771-5436","authenticated-orcid":false,"given":"Robin S.","family":"Everhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10212","key":"10.1016\/j.rmed.2026.108908_bib1","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.rmed.2026.108908_bib2","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.rmed.2026.108908_bib3","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-Tezacaftor-Ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2026.108908_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1156621","article-title":"Individualized approach to elexacaftor\/tezacaftor\/ivacaftor dosing in cystic fibrosis, in response to self-reported anxiety and neurocognitive adverse events: a case series","volume":"14","author":"Ibrahim","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.rmed.2026.108908_bib5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jcf.2022.08.018","article-title":"Non-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor\/tezacaftor\/ivacaftor","volume":"22","author":"Fajac","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.rmed.2026.108908_bib6","series-title":"Elexacaftor\/tezacaftor\/ivacaftor and Mental Health: a Workshop Report from the Cystic Fibrosis Foundation's Prioritizing Research in Mental Health Working Group","author":"Bathgate","year":"2024"},{"key":"10.1016\/j.rmed.2026.108908_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1179208","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on mental health of patients with cystic fibrosis","volume":"14","author":"Piehler","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.rmed.2026.108908_bib8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s41687-025-00879-0","article-title":"Improved quality of life in cystic fibrosis patients observed up to 36 months after starting Elexacaftor\/tezacaftor\/ivacaftor treatment","volume":"9","author":"Francesca","year":"2025","journal-title":"J. Patient-Rep. Outcomes"},{"issue":"1","key":"10.1016\/j.rmed.2026.108908_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.27382","article-title":"Heterogeneity in reported side effects following initiation of elexacaftor-tezacaftor-ivacaftor: experiences at a Quaternary CF care center","volume":"60","author":"Papadakis","year":"2025","journal-title":"Pediatr. Pulmonol."},{"issue":"3","key":"10.1016\/j.rmed.2026.108908_bib10","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.chest.2024.03.033","article-title":"Relationship between lung volumes and heterogeneity in the response to elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis and advanced lung disease","volume":"166","author":"Gramegna","year":"2024","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.rmed.2026.108908_bib11","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.jcf.2024.04.013","article-title":"Heterogeneity in response to elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis","volume":"23","author":"Alicandro","year":"2024","journal-title":"J. Cyst. Fibros."},{"issue":"4","key":"10.1016\/j.rmed.2026.108908_bib12","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jcf.2024.02.001","article-title":"Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosis","volume":"23","author":"Zemanick","year":"2024","journal-title":"J. Cyst. Fibros."},{"issue":"1","key":"10.1016\/j.rmed.2026.108908_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.27393","article-title":"Mental health of pediatric patients with cystic fibrosis after 18 months on elexacaftor-tezacaftor-ivacaftor therapy","volume":"60","author":"Pasley","year":"2025","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.rmed.2026.108908_bib14","article-title":"Mental health, behaviour and sleep quality in children 6\u201311 years before and after elexacaftor\/tezacaftor\/ivacaftor initiation","author":"Douglas","year":"2024","journal-title":"J. Cyst. Fibros."},{"issue":"8","key":"10.1016\/j.rmed.2026.108908_bib15","article-title":"Addressing symptom burden and palliative care needs in cystic fibrosis: a narrative review of the literature","volume":"13","author":"DiFiglia","year":"2023","journal-title":"Life (Basel)"},{"issue":"1","key":"10.1016\/j.rmed.2026.108908_bib16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.17294\/2330-0698.2050","article-title":"Adult development and associated health risks","volume":"11","author":"Halloran","year":"2024","journal-title":"J Patient Cent Res Rev."},{"issue":"5","key":"10.1016\/j.rmed.2026.108908_bib17","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.jcf.2023.04.015","article-title":"Partners in research: the success with therapies research consortium and the CF community unite to improve self-management","volume":"22","author":"Sawicki","year":"2023","journal-title":"J. Cyst. Fibros."},{"issue":"9","key":"10.1016\/j.rmed.2026.108908_bib18","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1002\/ppul.26527","article-title":"Positive and negative impacts of elexacaftor\/tezacaftor\/ivacaftor: Healthcare providers' observations across US centers","volume":"58","author":"Bathgate","year":"2023","journal-title":"Pediatr. Pulmonol."},{"issue":"2","key":"10.1016\/j.rmed.2026.108908_bib19","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jcf.2021.10.002","article-title":"Mental status changes during elexacaftor\/tezacaftor\/ivacaftor therapy","volume":"21","author":"Heo","year":"2022","journal-title":"J. Cyst. Fibros."},{"issue":"5","key":"10.1016\/j.rmed.2026.108908_bib20","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jcf.2022.03.010","article-title":"Obesity in Cystic fibrosis: prevalence, trends and associated factors data from the US cystic fibrosis foundation patient registry","volume":"21","author":"Szentpetery","year":"2022","journal-title":"J. Cyst. Fibros."},{"issue":"1","key":"10.1016\/j.rmed.2026.108908_bib21","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12931-023-02451-0","article-title":"Heterogeneity of weight gain after initiation of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis","volume":"24","author":"Gramegna","year":"2023","journal-title":"Respir. Res."},{"issue":"2","key":"10.1016\/j.rmed.2026.108908_bib22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J. Cyst. Fibros."},{"issue":"4","key":"10.1016\/j.rmed.2026.108908_bib23","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jcf.2025.01.010","article-title":"Longer term follow-up of abdominal symptoms (CFAbd-Score) after initiation of elexacaftor\/tezacaftor\/ivacaftor in adults with cystic fibrosis","volume":"24","author":"Caley","year":"2025","journal-title":"J. Cyst. Fibros."},{"issue":"5","key":"10.1016\/j.rmed.2026.108908_bib24","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.jcf.2025.09.003","article-title":"The novel CFAbd-Score.kid(\u24b8) reveals a significant decline of abdominal symptoms in children with Cystic fibrosis aged 6 through 11 years on elexacaftor\/tezacaftor\/ivacaftor - first results","volume":"24","author":"Mainz","year":"2025","journal-title":"J. Cyst. Fibros."},{"issue":"4","key":"10.1016\/j.rmed.2026.108908_bib25","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.chest.2023.10.043","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor: multidimensional assessment of neuropsychological side effects and physical and mental health outcomes in adolescents and adults","volume":"165","author":"Graziano","year":"2024","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.rmed.2026.108908_bib26","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1159\/000524773","article-title":"Effect of triple combination CFTR modulator therapy on sleep in adult patients with cystic fibrosis","volume":"101","author":"Welsner","year":"2022","journal-title":"Respiration"},{"issue":"6","key":"10.1016\/j.rmed.2026.108908_bib27","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jcf.2022.05.001","article-title":"Dose adjustments of elexacaftor\/tezacaftor\/ivacaftor in response to mental health side effects in adults with cystic fibrosis","volume":"21","author":"Spoletini","year":"2022","journal-title":"J. Cyst. Fibros."},{"issue":"7","key":"10.1016\/j.rmed.2026.108908_bib28","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/ppul.26412","article-title":"Management of neuropsychiatric symptoms in adults treated with elexacaftor\/tezacaftor\/ivacaftor","volume":"58","author":"Baroud","year":"2023","journal-title":"Pediatr. Pulmonol."},{"issue":"4","key":"10.1016\/j.rmed.2026.108908_bib29","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.psym.2017.04.001","article-title":"Cystic fibrosis transmembrane regulator modulators: implications for the management of depression and anxiety in cystic fibrosis","volume":"58","author":"Talwalkar","year":"2017","journal-title":"Psychosomatics"},{"issue":"6","key":"10.1016\/j.rmed.2026.108908_bib30","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.psym.2020.06.021","article-title":"Trikafta and psychopathology in cystic fibrosis: a case report","volume":"61","author":"Tindell","year":"2020","journal-title":"Psychosomatics"},{"issue":"2","key":"10.1016\/j.rmed.2026.108908_bib31","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jcf.2024.11.006","article-title":"Elexacaftor\/tezacaftor\/ivacaftor and mental health: a workshop report from the cystic fibrosis Foundation's prioritizing research in mental health working group","volume":"24","author":"Bathgate","year":"2025","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.rmed.2026.108908_bib32","doi-asserted-by":"crossref","DOI":"10.1177\/13591053261431710","article-title":"Body image and nutritional health in people with cystic fibrosis taking elexacaftor\/tezacaftor\/ivacaftor","author":"Lyons","year":"2026","journal-title":"J. Health Psychol."},{"key":"10.1016\/j.rmed.2026.108908_bib33","article-title":"What the future holds: cystic fibrosis and aging","volume":"10","author":"Blankenship","year":"2023","journal-title":"Front. Med. (Lausanne)"},{"issue":"6","key":"10.1016\/j.rmed.2026.108908_bib34","article-title":"Future comorbidities in an aging cystic fibrosis population","volume":"13","author":"Ticona","year":"2023","journal-title":"Life (Basel)"},{"issue":"6","key":"10.1016\/j.rmed.2026.108908_bib35","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.jcf.2024.08.007","article-title":"Cystic fibrosis foundation position paper: redefining the CF care model","volume":"23","author":"Goetz","year":"2024","journal-title":"J. Cyst. Fibros."},{"issue":"6","key":"10.1016\/j.rmed.2026.108908_bib36","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.jcf.2024.09.002","article-title":"Adapting the cystic fibrosis care model: perspectives from people with CF, caregivers, and members of CF care teams","volume":"23","author":"Tran","year":"2024","journal-title":"J. Cyst. Fibros."},{"issue":"6","key":"10.1016\/j.rmed.2026.108908_bib37","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/ppul.26400","article-title":"National integration of mental health screening and treatment into specialized care for cystic fibrosis: what predicts success?","volume":"58","author":"Quittner","year":"2023","journal-title":"Pediatr. Pulmonol."},{"issue":"11","key":"10.1016\/j.rmed.2026.108908_bib38","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1002\/ppul.24949","article-title":"Integration of mental health screening and treatment into cystic fibrosis clinics: evaluation of initial implementation in 84 programs across the United States","volume":"55","author":"Quittner","year":"2020","journal-title":"Pediatr. Pulmonol."},{"issue":"2","key":"10.1016\/j.rmed.2026.108908_bib39","doi-asserted-by":"crossref","first-page":"255","DOI":"10.5664\/jcsm.8986","article-title":"Behavioral and psychological treatments for chronic insomnia disorder in adults: an American academy of sleep medicine clinical practice guideline","volume":"17","author":"Edinger","year":"2021","journal-title":"J. Clin. Sleep Med."},{"issue":"2","key":"10.1016\/j.rmed.2026.108908_bib40","doi-asserted-by":"crossref","first-page":"239","DOI":"10.7326\/M22-2056","article-title":"Nonpharmacologic and pharmacologic treatments of adults in the acute phase of major depressive disorder: a living clinical guideline from the American college of physicians","volume":"176","author":"Qaseem","year":"2023","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/j.rmed.2026.108908_bib41","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jcf.2024.11.012","article-title":"Addressing pain in people living with cystic fibrosis: cystic fibrosis foundation evidence-informed guidelines","volume":"24","author":"Dellon","year":"2025","journal-title":"J. Cyst. Fibros."},{"issue":"1","key":"10.1016\/j.rmed.2026.108908_bib42","article-title":"ACG clinical guideline: management of irritable bowel syndrome","volume":"116","author":"Lacy","year":"2021","journal-title":"Off. J. Am. Coll. Gastroenterol. ACG."},{"issue":"6","key":"10.1016\/j.rmed.2026.108908_bib43","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s12529-023-10254-2","article-title":"Efficacy and acceptance of cognitive behavioral therapy in adults with chronic fatigue syndrome: a meta-analysis","volume":"31","author":"Maas Genannt Bermpohl","year":"2024","journal-title":"Int. J. Behav. Med."},{"key":"10.1016\/j.rmed.2026.108908_bib44","article-title":"Coping and learning to manage stress with cystic fibrosis (CALM): a multisite telehealth randomized controlled trial to reduce depression and anxiety symptoms in adults with cystic fibrosis","author":"Bathgate","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.rmed.2026.108908_bib45","unstructured":"Jensen MKN, O'Connell ME, Mickleborough MJS. Perceptions of health, cognition, and pain among middle-aged and older adults with migraine: a population-based cross-sectional study examining findings from the Canadian longitudinal study on aging. Headache J. Head Face Pain.n\/a(n\/a)."},{"issue":"3","key":"10.1016\/j.rmed.2026.108908_bib46","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.socscimed.2009.05.013","article-title":"What is self-rated health and why does it predict mortality? Towards a unified conceptual model","volume":"69","author":"Jylh\u00e4","year":"2009","journal-title":"Soc. Sci. Med."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126002763?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126002763?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T01:53:58Z","timestamp":1783130038000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611126002763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":46,"alternative-id":["S0954611126002763"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2026.108908","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"People with cystic fibrosis\u2019 experience of symptom burden while taking elexacaftor\/tezacaftor\/ivacaftor","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2026.108908","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108908"}}